Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

EASD 2026
EASD 2026 28 September - 2 October 2026

HbA1c-independent benefits of semaglutide on liver histology and non-invasive tests in participants with biopsy-defined MASH: insights from post hoc analysis of the ESSENCE trial part 1

Authors :

P.N. Newsome1, A.J. Sanyal2, E. Bugianesi3, M.T. Arias-Loste4, L. Castera5, N.M. Eklöf6, W. Kim7, N. Krarup6, B. Ludvik8, V. Ratziu9, M.E. Rinella10, A. Trifan11, T.C. Vestergaard6, M. Roden12, on behalf of the ESSENCE Study Group
Affiliations
View Details Hide Details
Download poster (.pdf)
{{ getPageNum(PDFPage) }}
Keywords
MASH
Congress short oral presentation
GLP-1 RA
Semaglutide
PHASE 3 (RCT)